Reversal of impaired hippocampal long-term potentiation and contextual fear memory deficits in angelman syndrome model mice by ErbB inhibitors

Biological Psychiatry

Volumn 72, Issue 3, 2012, Pages 182-190

  Kaphzan, Hanoch ^a   Hernandez, Pepe ^b   Jung, Joo In ^a   Cowansage, Kiriana K ^a   Deinhardt, Katrin ^c   Chao, Moses V ^c   Abel, Ted ^b   Klann, Eric ^a  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angelman syndrome; ErbB4; hippocampus; interneurons; LTP; NRG1

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; NEU DIFFERENTIATION FACTOR;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HAPPY PUPPET SYNDROME; HIPPOCAMPUS; LEARNING; LONG TERM POTENTIATION; MEMORY; MEMORY DISORDER; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANGELMAN SYNDROME; ANIMALS; BLOTTING, WESTERN; CHLORIDE CHANNELS; COGNITION DISORDERS; ELECTROPHYSIOLOGICAL PHENOMENA; EXTRACELLULAR SPACE; FEAR; HIPPOCAMPUS; IMMUNOPRECIPITATION; LONG-TERM POTENTIATION; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; NEUREGULIN-1; ONCOGENE PROTEINS V-ERBB; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; SYNAPSES; SYNAPTIC TRANSMISSION; UBIQUITIN-PROTEIN LIGASES;

EID: 84863677318     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.01.021     Document Type: Article

References (61)

1. Lossie AC, Whitney MM, Amidon D, Dong HJ, Chen P, Theriaque D, et al. (2001): Distinct phenotypes distinguish the molecular classes of Angelman syndrome. J Med Genet 38:834-845. (Pubitemid 34014208)
2. Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA, et al. (2006): Angelman syndrome 2005: Updated consensus for diagnostic criteria. Am J Med Genet A 140:413-418. (Pubitemid 43376311)
3. Kishino T, Lalande M, Wagstaff J (1997): UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 15:70 -73.
4. Knoll JH, Nicholls RD, Magenis RE, Graham JM Jr, Lalande M, Latt SA (1989): Angelman and Prader-Willi syndromes share a common chromosome 15 deletion but differ in parental origin of the deletion. Am J Med Genet 32:285-290.
5. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, et al. (1997): De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 15:74-77. (Pubitemid 27014953)
6. Sutcliffe JS, Jiang YH, Galijaard RJ, Matsuura T, Fang P, Kubota T, et al. (1997): The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region. Genome Res 7:368-377. (Pubitemid 27183005)
7. Gustin RM, Bichell TJ, Bubser M, Daily J, Filonova I, Mrelashvili D, et al. (2010): Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome. Neurobiol Dis 39:283-291.
8. Albrecht U, Sutcliffe JS, Cattanach BM, Beechey CV, Armstrong D, Eichele G, Beaudet AL (1997): Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet 17:75-78. (Pubitemid 27377535)
9. Jiang Y, Tsai TF, Bressler J, Beaudet AL (1998): Imprinting in Angelman and Prader-Willi syndromes. Curr Opin Genet Dev 8:334-342. (Pubitemid 28340086)
10. Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, et al. (1998): Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and longterm potentiation. Neuron 21:799-811. (Pubitemid 28498788)
11. van Woerden GM, Harris KD, Hojjati MR, Gustin RM, Qiu S, de Avila Freire R, et al. (2007): Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. Nat Neurosci 10:280 -282.
12. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, et al. (1992): Identification of heregulin, a specific activator of p185erbB2. Science 256:1205-1210.
13. Fischbach GD, Rosen KM (1997): ARIA: A neuromuscular junction neuregulin. Annu Rev Neurosci 20:429-458. (Pubitemid 27106389)
14. Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, et al. (2000): Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. Neuron 26:443- 455.
15. Kwon OB, Longart M, Vullhorst D, Hoffman DA, Buonanno A (2005): Neuregulin-1 reverses long-term potentiation at CA1 hippocampal synapses. J Neurosci 25:9378-9383. (Pubitemid 41464750)
16. Pitcher GM, Beggs S, Woo RS, Mei L, Salter MW (2008): ErbB4 is a suppressor of long-term potentiation in the adult hippocampus. Neuroreport 19:139-143.
17. Ehrlichman RS, Luminais SN, White SL, Rudnick ND, Ma N, Dow HC, et al. (2009): Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. Brain Res 1294:116 -127.
18. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, et al. (2006): Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12:824-828. (Pubitemid 44050073)
19. Mei L, Xiong WC (2008): Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9:437-452. (Pubitemid 351704944)
20. Corfas G, Roy K, Buxbaum JD (2004): Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 7:575-580. (Pubitemid 38691892)
21. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. (2002): Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877-892. (Pubitemid 135750519)
22. Iossifov I, Zheng T, Baron M, Gilliam TC, Rzhetsky A (2008): Geneticlinkage mapping of complex hereditary disorders to a whole-genome molecular-interaction network. Genome Res 18:1150-1162. (Pubitemid 351931166)
23. Falls DL (2003): Neuregulins: Functions, forms, and signaling strategies. Exp Cell Res 284:14 -30.
24. Woo RS, Li XM, Tao Y, Carpenter-Hyland E, Huang YZ, Weber J, et al. (2007): Neuregulin-1 enhances depolarization-induced GABA release. Neuron 54:599-610. (Pubitemid 46756135)
25. Sorkin A, Goh LK (2009): Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315:683- 696.
26. Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce CM, et al. (2008): Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A 105:4162- 4167.
27. Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL (2007): The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet 17:111-118.
28. Gu Z, Jiang Q, Fu AK, Ip NY, Yan Z (2005): Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci 25:4974-4984. (Pubitemid 40712840)
29. Lee HK, Takamiya K, Han JS, Man H, Kim CH, Rumbaugh G, et al. (2003): Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. Cell 112:631-643. (Pubitemid 36331776)
30. Bjarnadottir M, Misner DL, Haverfield-Gross S, Bruun S, Helgason VG, Stefansson H, et al. (2007): Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: Differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. J Neurosci 27:4519-4529. (Pubitemid 46663586)
31. Kaushansky A, Gordus A, Budnik BA, Lane WS, Rush J, MacBeath G (2008): System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. Chem Biol 15:808-817.
32. Anton ES, Marchionni MA, Lee KF, Rakic P (1997): Role of GGF/neuregulin signaling in interactions between migrating neurons and radial glia in the developing cerebral cortex. Development 124:3501-3510. (Pubitemid 27470034)
33. Roy K, Murtie JC, El-Khodor BF, Edgar N, Sardi SP, Hooks BM, et al. (2007): Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci U S A 104:8131-8136. (Pubitemid 47185887)
34. Gerecke KM, Wyss JM, Karavanova I, Buonanno A, Carroll SL (2001): ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system. J Comp Neurol 433:86-100.
35. Mizuno M, Iwakura Y, Shibuya M, Zheng Y, Eda T, Kato T, et al. (2010): Antipsychotic potential of quinazoline ErbB1 inhibitors in a schizophrenia model established with neonatal hippocampal lesioning. J Pharmacol Sci 114:320 -331.
36. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. (2001): Genome-wide expression analysis reveals dysregulation of myelination- related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98:4746-4751. (Pubitemid 32295047)
37. Weeber EJ, Jiang YH, Elgersma Y, Varga AW, Carrasquillo Y, Brown SE, et al. (2003): Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J Neurosci 23:2634-2644. (Pubitemid 36418598)
38. Chen YJ, Zhang M, Yin DM, Wen L, Ting A, Wang P, et al. (2010): ErbB4 in parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-term potentiation. Proc Natl Acad Sci U S A 107:21818-21823.
39. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, et al. (2008): Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 14:843- 848.
40. Hoeffer CA, Klann E (2010): mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci 33:67-75.
41. Blundell J, Kouser M, Powell CM (2008): Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation. Neurobiol Learn Mem 90:28-35.
42. Gafford GM, Parsons RG, Helmstetter FJ (2011): Consolidation and reconsolidation of contextual fear memory requires mammalian target of rapamycin-dependent translation in the dorsal hippocampus. Neuroscience 182:98-104.
43. Krivosheya D, Tapia L, Levinson JN, Huang K, Kang Y, Hines R, et al. (2008): ErbB4-neuregulin signaling modulates synapse development and dendritic arborization through distinct mechanisms. J Biol Chem 283:32944-32956.
44. Wen L, Lu YS, Zhu XH, Li XM, Woo RS, Chen YJ, et al. (2010): Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc Natl Acad Sci U S A 107:1211-1216.
45. Neddens J, Buonanno A (2010): Selective populations of hippocampal interneurons express ErbB4 and their number and distribution is altered in ErbB4 knockout mice. Hippocampus 20:724-744.
46. Vullhorst D, Neddens J, Karavanova I, Tricoire L, Petralia RS, McBain CJ, Buonanno A (2009): Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. J Neurosci 29:12255-12264.
47. Laan LA, Vein AA (2005): Angelman syndrome: Is there a characteristic EEG? Brain Dev 27:80-87.
48. Fiumara A, Pittala A, Cocuzza M, SorgeG(2010): Epilepsy in patients with Angelman syndrome. Ital J Pediatr 36:31.
49. Clayton-Smith J, Laan L (2003): Angelman syndrome: A review of the clinical and genetic aspects. J Med Genet 40:87-95. (Pubitemid 36232812)
50. Noebels JL (2003): The biology of epilepsy genes. Annu Rev Neurosci 26:599-625.
51. Steinlein OK (2002): Channelopathies can cause epilepsy in man. Eur J Pain 6(suppl A):27-34.
52. Steinlein OK, BertrandD(2010): Nicotinic receptor channelopathies and epilepsy. Pflugers Arch 460:495-503.
53. Sotiriou E, Papatheodoropoulos C, Angelatou F (2005): Differential expression of gamma-aminobutyric acid-a receptor subunits in rat dorsal and ventral hippocampus. J Neurosci Res 82:690-700. (Pubitemid 41740469)
54. Hentschke H, Benkwitz C, Banks MI, Perkins MG, Homanics GE, Pearce RA (2009): Altered GABAA, slow inhibition and network oscillations in mice lacking the GABAA receptor beta3 subunit. J Neurophysiol 102:3643-3655.
55. Dan B (2009): Angelman syndrome: Current understanding and research prospects. Epilepsia 50:2331-2339.
56. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, Garner CC (2007): Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 10:411-413. (Pubitemid 46494581)
57. Bhattacharyya A, McMillan E, Chen SI, Wallace K, Svendsen CN (2009): A critical period in cortical interneuron neurogenesis in down syndrome revealed by human neural progenitor cells. Dev Neurosci 31:497-510.
58. Perez-Cremades D, Hernandez S, Blasco-Ibanez JM, Crespo C, Nacher J, Varea E (2010): Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J Neural Transm 117:445- 455.
59. Rachidi M, Lopes C (2008): Mental retardation and associated neurological dysfunctions in Down syndrome: A consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur J Paediatr Neurol 12:168-182. (Pubitemid 351545848)
60. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM (2010): Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 30:9929-9938.
61. Selby L, Zhang C, SunQQ(2007): Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neurosci Lett 412:227-232. (Pubitemid 46109160)